Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Oct 6;14(19):4894. doi: 10.3390/cancers14194894

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Ranking plot based simultaneously on efficacy (x-axis: SUCRA value of progression free survival (PFS) or overall survival (OS)) and tolerability (y-axis: SUCRA value of adverse events of grade 3 or higher (≥Grade 3 AEs)). (A) Ranking plot based simultaneously SUCRA value of PFS and SUCRA value of ≥Grade 3 AE; (B) Ranking plot based simultaneously SUCRA value of OS and SUCRA value of ≥Grade 3 AE. SUCRA, surface under the cumulative ranking curves; TKIplusP: TKI plus pemetrexed; TKIplusPC: TKI plus pemetrexed and carboplatin; TKIplusBev: TKI plus bevacizumab; TKIplusRam: TKI plus ramucirumab; TKIplusApa: TKI plus apatinib; TKIplusLin: TKI plus linsitinib; TKIplusMet: TKI plus metformin; TKIplusOla: TKI plus Olaparib.